3:51 PM
 | 
Sep 13, 2018
 |  BC Extra  |  Financial News

Surface Oncology execs join MPM

MPM Capital hired Detlev Biniszkiewicz and Scott Chappel as executive partners. They will be responsible for identifying and evaluating new oncology investment opportunities for MPM, as well as portfolio oversight.

Biniszkiewicz and Chappel are former executives of Surface Oncology Inc. (NASDAQ:SURF), where they guided the immuno-oncology company into the clinic and public market. Surface raised $108 million in an IPO in April.

Biniszkiewicz was Surface president and CEO. Chappel co-founded the company and was its CTO.

Chappel is also CSO of cancer company iTeos Therapeutics S.A. (Gosselies, Belgium).

Before joining Surface, Biniszkiewicz was VP of strategy in the oncology unit of AstraZeneca plc (LSE:AZN; NYSE:AZN).

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

Purchase this article for limited one-time distribution and website posting

$750 USD